Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2019 · 10-Q
Revenue$62.02K$62.02K−38.1% vs Q1 2018 Net Income-$3.90M-$3.90MN/M vs Q1 2018 EPS Diluted-$1.02-$1.02N/M vs Q1 2018 Operating Income-$3,961,763N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,365,320N/M Margins · derivedOperating margin-6387.8%−1739.1 pt vs Q1 2018
Net margin-6295.9%−1516.2 pt vs Q1 2018
ended Mar 31, 2019 · filed May 7, 2019 · 37 d after period end